![]() 5.3 months (p < 0.0001) and similar OS for PEM vs. Median PFS and OS were 3.9 and 8.7 months with weighted PFS of 3.9 vs. The overall response rate was 27.5% with a higher response rate of 37.8% (range, 29.7-46.7%) for TAXs-based treatment vs. We tested for significant heterogeneity by Cochran's chi-square test and I(2) index.Įleven studies published between 19 were included in this analysis with a total of 607 patients enrolled 468 were treated with PEM-doublets and 139 with TAXs-doublets. ![]() Median weighted progression-free survival (PFS) and overall survival (OS) time for PEM and TAXs-based doublets were compared by two-sided Student's t test. A systematic review was conducted using Comprehensive Meta-Analysis (version 2.2.064) software to calculate the event rate of response and 95% confidence interval. Pemetrexed and taxanes (TAXs)-based platinum combinations were considered. Studies that enrolled NSCLC platinum pre-treated patients were identified using electronic databases (MEDLINE and EMBASE). The potential usefulness of platinum-based doublets as rechallenge for second-line chemotherapy has not yet been established. The sole agents pemetrexed (PEM), docetaxel and anti-EGFR agents are approved second-line therapies for non-small cell lung cancer (NSCLC) after failure with cisplatin-based doublets. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |